Cancer Database Query Results

Scientific Papers found: Click to Expand⟱

2239-

MF,

Time-varying magnetic fields increase cytosolic free Ca2+ in HL-60 cells

in-vitro,

AML,

HL-60

Ca+2↑, eff↝,

2240-

MF,

Pulsed electromagnetic field induces Ca2+-dependent osteoblastogenesis in C3H10T1/2 mesenchymal cells through the Wnt-Ca2+/Wnt-β-catenin signaling pathway

in-vitro,

Nor,

C3H10T1/2

30 Hz, 1 mT, 2 h/day

PEMF output waveform consisted of a 400 kV/m pulsed burst (pulse width 0.2 m s; pulse wait 0.02 m s; burst width 5 m s; burst wait 60 m s; pulse rise 0.3 m s; pulse fall 2.0 m s) repeated at 30 Hz.

*Ca+2↑, *Diff↑, *BMD↑, *Wnt↑, *β-catenin/ZEB1↑, *eff↝,

2261-

MF,

Tumor-specific inhibition with magnetic field

in-vitro,

Nor,

GP-293

5 mT, 2h/day, 3 days

in-vitro,

Liver,

HepG2

in-vitro,

Lung,

A549

ROS↑, Ca+2↓, Apoptosis↑, *selectivity↑, TumCG↓, *i-Ca+2↓, i-Ca+2↑,

2260-

MF,

Alternative magnetic field exposure suppresses tumor growth via metabolic reprogramming

in-vitro,

GBM,

U87MG

18 mT at the center

in-vitro,

GBM,

LN229

in-vivo,

NA,

AMF for 30 min daily, for a total of five sessions.

mice

TumCP↓, TumCG↓, OS↑, ROS↑, SOD2↑, eff↓, ECAR↓, OCR↑, selectivity↑, *toxicity∅, TumVol↓, PGC-1α↑, OXPHOS↑, Glycolysis↓, PKM2↓,

2256-

MF,

HPT,

Effects of exposure to repetitive pulsed magnetic stimulation on cell proliferation and expression of heat shock protein 70 in normal and malignant cells

in-vitro,

BC,

MCF7

34mT, 50Hz 2-s bursts and 1-s rests.

in-vitro,

Cerv,

HeLa

in-vitro,

Nor,

HBL-100

HSP70/HSPA5↑, HSP70/HSPA5∅,

2255-

MF,

Pulsed Electromagnetic Fields Induce Skeletal Muscle Cell Repair by Sustaining the Expression of Proteins Involved in the Response to Cellular Damage and Oxidative Stress

in-vitro,

Nor,

SkMC

1.5 mT PEMF for four hours repeated for two days

*HSP70/HSPA5↑, *Apoptosis↓, *Inflam↓, *Trx↓, *PONs↓, *SOD2↓, *TumCG↑, *Diff↑, *HIF2a↑, *Cyt‑c↑, P21↑,

2253-

MF,

Low-frequency pulsed electromagnetic field promotes functional recovery, reduces inflammation and oxidative stress, and enhances HSP70 expression following spinal cord injury

in-vivo,

Nor,

50 Hz frequency and 2.5 mT

spinal cord-injured rats.

*Inflam↓, *TNF-α↓, *IL1β↓, *NF-kB↓, *iNOS↓, *ROS↓, Catalase↑, *SOD↑, *HSP70/HSPA5↑, *neuroP↑, *motorD↑, *antiOx↑,

6939-

MF,

A prospective, randomized, placebo controlled, double-blind study of pelvic electromagnetic therapy for the treatment of chronic pelvic pain syndrome with 1 year of followup

Trial,

Nor,

 21 men with a mean age of 47.8 years

*Pain↓,

6938-

MF,

Effect of pulsed electromagnetic field therapy on prostate volume and vascularity in the treatment of benign prostatic hyperplasia: a pilot study in a canine model

in-vivo,

BPH,

dog

*Dose↝, *toxicity↓, *BloodF↑, *Dose↝, *PV↓, *Inflam↓,

6937-

MF,

Noninvasive treatment for men suffering from enlarged prostate

Review,

BPH,

*PV↓, *Inflam↓, *BloodF↑, *Dose↝,

6936-

MF,

Ex,

Pulsed electromagnetic field with or without exercise therapy in the treatment of benign prostatic hyperplasia

Trial,

BPH,

Sixty male patients aged 55–65 years with benign prostatic hyperplasia

*eff↑, *Synergy↑, *BloodF↑, *Diff↝, *Dose↝, *Dose↝, *Dose↝, *Dose↝, *Dose↝, *Dose↝, *Dose↝, *UFR↑, *UR↓, *PSA↓, *other↑, *Inflam↓,

6942-

MF,

Emerging techniques in ‘truly’ minimal-invasive treatment options of benign prostatic obstruction

Review,

BPH,

PV↓,

6941-

MF,

Ex,

The effects of pulsed electromagnetic field therapy on muscle strength and pain in patients with end-stage knee osteoarthritis: a randomized controlled trial

Trial,

Arthritis,

Sixty patients OA

*Strength↑, *Pain↓, *eff↑, *Dose↝,

6940-

MF,

Meta-analysis of the effectiveness and safety of magnetic stimulation for chronic pelvic pain

Review,

BPH,

*UFR↑, *other?, *Pain↓, *BloodF↑, *other↑, *Inflam↓, *QoL↑,

4568-

MF,

Extremely low-frequency pulses of faint magnetic field induce mitophagy to rejuvenate mitochondria

Study,

NA,

*ETC↓, *OCR↑, *MMP↑, *ROS⇅, *MMP⇅,

4571-

MF,

Magnetic Fields and Reactive Oxygen Species

Review,

NA,

*ROS⇅, *ETC↓, Dose↝, Dose↝,

4351-

MF,

Inhibition of proliferation of human lymphoma cells U937 by a 50 Hz electromagnetic field

in-vitro,

lymphoma,

>3.5mT 50 Hz

Apoptosis↑,

4349-

MF,

Long-term effect of full-body pulsed electromagnetic field and exercise protocol in the treatment of men with osteopenia or osteoporosis: A randomized placebo-controlled trial

Trial,

ostP,

0.01–15,000 Hz, with sinusoidal, rectangular, multi-resonance, impulse, or sawtooth waveforms, the full-body maximum intensity is 30 gauss (3,000 microTesla)

Ninety-five males with osteopenia or osteoporosis

*BMD↑, *Pain↓, *QoL↑, *toxicity↓, *Dose↝, *Inflam↓,

4348-

MF,

Pulsed electromagnetic field attenuates bone fragility in estrogen-deficient osteoporosis in rats

in-vivo,

ostP,

 (40 Hz and 25 Hzk), intensities (10 mT and 36.4 μT)

*BMD↑,

4352-

MF,

Differences in lethality between cancer cells and human lymphocytes caused by LF-electromagnetic fields

in-vitro,

lymphoma,

K562

B < or = 15 mT 50/60 Hz

NA,

U937

NA,

HL-60

Apoptosis↑, Synergy↑,

4353-

MF,

Chemo,

Pulsed Electromagnetic Field Enhances Doxorubicin-induced Reduction in the Viability of MCF-7 Breast Cancer Cells

in-vitro,

BC,

MCF7

 1 hours PEMF session (2.5 mT at 70 Hz) thrice a day for three consecutive days.

TumCCA↑, Apoptosis↑, ChemoSen↑, TumCCA↑, Casp↝, p‑CDK2↓, cycE/CCNE↓, Fas↑, BAX↑, survivin↓, Mcl-1↓, cl‑PARP↑, cl‑Casp7↑, cl‑Casp8↑, cl‑Casp9↑,

4354-

MF,

doxoR,

Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach

in-vivo,

BC,

MDA-MB-231

3mT, PEMFs stimulation for 1 h weekly for 5 weeks

NSG mice were purchased from The Jackson’s Laboratory and used at 8-10 weeks of age.

in-vivo,

BC,

MCF7

selectivity↑, Apoptosis↑, TumCI↓, tumCV↓, TumVol↓, eff↓, ChemoSen↑, ROS↑, Ca+2↑, TumCMig↓,

4355-

MF,

Ambient and supplemental magnetic fields promote myogenesis via a TRPC1-mitochondrial axis: evidence of a magnetic mitohormetic mechanism

in-vitro,

Nor,

C2C12

 1.5 mT

C2C12 mouse skeletal myoblasts

*mt-OCR↑, *mt-ROS↑, *ECAR↑, *Dose↝, *Ca+2↑, *ATP↑, *other↑, *eff↓, *eff↝,

4356-

MF,

Pulsed electromagnetic fields synergize with graphene to enhance dental pulp stem cell-derived neurogenesis by selectively targeting TRPC1 channels

in-vitro,

Nor,

(10 min) and low amplitude (2 mT) PEMF

human dental pulp stem cells (hDPSCs)

*Diff↑, *TRPC1↑, *ROS↑,

4425-

MF,

doxoR,

Brief Magnetic Field Exposure Stimulates Doxorubicin Uptake into Breast Cancer Cells in Association with TRPC1 Expression: A Precision Oncology Methodology to Enhance Chemotherapeutic Outcome

in-vitro,

BC,

4T1

in-vitro,

BC,

MCF7

ChemoSen↑, TRPC1↑, Dose↓, selectivity↑,

8483-

MF,

Magnetic Fields in Cancer Therapy: Mechanistic Insights, Signaling Pathways, and Evidence from Clinical and In Vitro Studies

Review,

Var,

Apoptosis↑, TumCP↓, Ferroptosis↑, TumCMig↓, EMT↓, ROS↝, ChemoSen↑, RadioS↑, Telomerase↓, selectivity↑, ROS↑, DNAdam↑, Casp↑, Ca+2↑, MMP↓, lysoMP↑, lipid-P↑, NA↑, other↑, ChemoSen↑, P53↑,

8491-

MF,

Chemo,

Chemotherapy of human carcinoma xenografts during pulsed magnetic field exposure

in-vivo,

CRC,

HT-29

mice

NA,

Melanoma,

A431

Dose↝, Dose↝, TumVol↓,

8490-

MF,

Induction of apoptosis in B16-BL6 melanoma cells following exposure to electromagnetic fields modeled after intercellular calcium waves

in-vitro,

Melanoma,

B16-BL6

TumCP↓, Apoptosis↑, tumCV↓,

8489-

MF,

Pulsed electromagnetic fields induce ferroptosis in osteosarcoma cells and promote osteogenic differentiation

in-vitro,

OS,

U2OS

in-vitro,

OS,

MG63

TumCP↓, TumCMig↓, Ferroptosis↑, GPx4↓, xCT/SLC7A11↓, BMD↑, selectivity↑, Dose↝, TumCG↓, Dose↝, OS↑, ROS↑, MDA↑, Iron↑, ChemoSen↑, TOP2↑, radioP↑,

8488-

MF,

Efficacy and Durability of Repetitive Transcranial Magnetic Stimulation on Cognitive Function in Patients With Mild-to-Moderate Alzheimer's Disease: A Systematic Review and Meta-Analysis

Review,

AD,

*eff↑, *cognitive↑, *Dose↝,

8487-

MF,

The effect of repetitive transcranial magnetic stimulation on immediate and long-term cognitive functions in Alzheimer's dementia and mild cognitive impairment: a meta-analysis

Review,

AD,

*cognitive↑, *Dose↝, *Dose↝, *BDNF↑, *neuroP↑,

8486-

MF,

Silent forces, hidden currents: the influence of static magnetic field stimulation on tumor biophysics

Review,

Var,

Ca+2↑, TumCG↓, MMP↓, CellMemb↑, SOX2↓, Nanog↓, cMyc↓, CD44↓, CD133↓, P53↑, ROS↑, DNAdam↑, CDK1↓, CycB/CCNB1↓, TumCCA↑, TumCP↓, pH↓, TumCP↓, Telomerase↓, ChemoSen↑, TRPV1↝, Bax:Bcl2↑, Casp3↑, Akt↓, mTOR↓, mitA↑, ROS↓, P-gp/ABCB1↓, MDR1↓, RadioS↑, Apoptosis↑, GSH↓, lipid-P↑, Iron↑, Iron↓, Fenton↑,

8485-

MF,

doxoR,

Static magnetic field promotes the doxorubicin toxicity effects on osteosarcoma cells

in-vitro,

OS,

G292

tumCV↓, Dose↝, Apoptosis↑, ROS↑, i-Iron↓, *Ca+2↓, *Iron↑, *chemoP↑, ROS↓, ChemoSen↑, selectivity↑,

8484-

MF,

doxoR,

Pulsed Electromagnetic Field Increases Doxorubicin-induced Mitotic Slippage in MDA-MB-231 Breast Cancer Cells

in-vitro,

BC,

MDA-MB-231

ChemoSen↑, Dose↝, eff↑, CDK1?, p‑H3↓, survivin↓, PLK1↓,

7391-

MF,

The effects of pulsed magnetic field exposure on the permeability of leukemia cancer cells

in-vitro,

AML,

K562

Dose↝, Ca+2↓, eff↑,

7390-

MF,

A 60-Hz sinusoidal magnetic field induces apoptosis of prostate cancer cells through reactive oxygen species

in-vitro,

Pca,

DU145

in-vitro,

Pca,

PC3

in-vitro,

Pca,

LNCaP

TumCG↓, Apoptosis↑, TumCCA↑, cl‑Casp3↑, ROS↑, eff↓, Dose↝, Dose↝, H2O2↑,

7389-

MF,

Modulation of Hydrogen Peroxide Production in Cellular Systems by Low Level Magnetic Fields

in-vitro,

Var,

HT1080

in-vitro,

PC,

AsPC-1

H2O2↑, ROS⇅,

7387-

MF,

Effects of Sinusoidal Magnetic Field Observed on Cell Proliferation, Ion Concentration, and Osmolarity in Two Human Cancer Cell Lines

in-vitro,

AML,

HL-60

in-vitro,

adrenal,

SK-HEP-1

Dose↝, TumCG↓, Na+↑, K+↑,

7383-

MF,

Magneto mitochondrial dysfunction mediated cancer cell death using intracellular magnetic nano-transducers

vitro+vivo,

Var,

mtDam↑, Apoptosis↑, MitoP↑, Dose↝, Dose↝, eff↑, PINK1↑, PARK2↑,

7384-

MF,

Reactive oxygen species (ROS) production in HepG2 cancer cell line through the application of localized alternating magnetic field

in-vitro,

Liver,

HepG2

ROS↑, tumCV↓, mtDam↑, Dose↝, ER Stress↑,

5534-

MF,

Targeted Osmotic Lysis of Highly Invasive Breast Carcinomas Using Pulsed Magnetic Field Stimulation of Voltage-Gated Sodium Channels and Pharmacological Blockade of Sodium Pumps

vitro+vivo,

BC,

MDA-MB-231

PMFs (0–80 mT, 10 msec pulses, 15 pps for 10 min)

xenografts in J/Nu mice or 4T1 homografts in BALB/c mice

in-vitro,

Nor,

MCF10

TumVol↓, VGSC↑, OS↑, selectivity↑, eff↑,

5533-

MF,

Magnetic field-induced drug permeability in liposome vesicles

in-vitro,

Nor,

*Dose↝, *CellMemb↑, *other↝,

5532-

MF,

Magnetoporation: New Method for Permeabilization of Cancerous Cells to Hydrophilic Drugs

in-vivo,

BC,

50 female Balb/c mice were tumorized via homograft.

Dose↑, CellMemb↑, eff↝, other↝, TumCG↓,

5531-

MF,

Effect of low frequency, low amplitude magnetic fields on the permeability of cationic liposomes entrapping carbonic anhydrase: I. Evidence for charged lipid involvement

in-vitro,

NA,

Dose↝, CellMemb↑,

5241-

MF,

A review on the use of magnetic fields and ultrasound for non-invasive cancer treatment

Review,

Var,

other↑, BloodF↑, Glycolysis↓, ATP↓, VEGF↓, ROS↑, P-gp/ABCB1↓, Apoptosis↑, selectivity↑, Ca+2↑, Catalase↑,

5247-

MF,

Anticancer Activity by Magnetic Fields: Inhibition of Metastatic Spread and Growth in a Breast Cancer Model

in-vivo,

BC,

MDA-MB-468

The nude mice, bearing a subcutaneous
human breast tumor (MDA-MB-435), were exposed for 70 min
daily

TumCI↓,

5246-

MF,

Chemo,

Non-ionizing Electromagnetic Radiation: A Study of Carcinogenic and Cancer Treatment Potential

in-vitro,

BC,

MCF7

ChemoSen↑,

4100-

MF,

Neurobiological effects and mechanisms of magnetic fields: a review from 2000 to 2023

Review,

Var,

*memory↑, *Mood⇅,

4102-

MF,

Modulation of antioxidant enzyme gene expression by extremely low frequency electromagnetic field in post-stroke patients

Human,

Stroke,

40 Hz frequency at 7 milliTesla, for 15 minutes per day, five days a week, over a four‑week

 Forty-eight post-stroke patients

*Catalase↑, *SOD1↑, *SOD2↑, *GPx1↑, *GPx4↑, *Dose↝,

4099-

MF,

Extremely low frequency electromagnetic field reduces oxidative stress during the rehabilitation of post-acute stroke patients

Trial,

Stroke,

57 post-stroke patients

*ROS↓,

Showing Research Papers: 6051 to 6100 of 8608
Prev Page 122 of 173 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8608

Pathway results for Effect on Cancer / Diseased Cells:

Ingredients & Constituents(tgid=25) ⓘ

Api↑, 1, Ingr?, 5, Ingr↑, 1, Ingr↝, 6,
Total Targets: 2896

Pathway results for Effect on Normal Cells:

NA, unassigned(tgid=0) ⓘ

NA↓, 1, NA↑, 1, NA↝, 1,

Redox & Oxidative Stress(tgid=1) ⓘ

3-NT↓, 1, 4-HNE↓, 6, antiOx?, 4, antiOx↓, 44, antiOx↑, 790, i-antiOx↑, 1, mt-antiOx↑, 1, ARE↑, 13, ARE↝, 1, Bil↓, 5, Bil↑, 2, Catalase↓, 9, Catalase↑, 254, Catalase↝, 2, Copper↓, 4, CoQ10↑, 1, DPPH↓, 2, DUOX1↓, 1, Fenton↓, 8, GCLC↑, 7, GCLC↝, 1, GCLM↑, 5, GCLM↝, 1, GPx↓, 6, GPx↑, 185, GPx↝, 1, GPx∅, 1, GPx1↑, 11, GPx3↑, 1, GPx4↓, 2, GPx4↑, 22, GPx4∅, 1, GSH↓, 17, GSH↑, 317, GSH⇅, 1, GSH∅, 2, GSH/GSSG↓, 1, GSH/GSSG↑, 3, GSR↓, 3, GSR↑, 38, GSS↑, 2, GSSG↓, 7, GSSG∅, 1, GSTs↓, 5, GSTs↑, 51, H2O2↓, 26, H2O2↑, 2, H2O2∅, 2, HDL↓, 3, HDL↑, 20, HDL∅, 4, HNE↓, 3, HNE↑, 1, HO-1?, 1, HO-1↓, 9, HO-1↑, 228, HO-1⇅, 1, HO-1↝, 1, HO-1∅, 1, HO-2↓, 1, hyperG↓, 2, Iron↓, 14, Iron↑, 2, Iron↝, 2, Iron∅, 1, i-Iron↓, 3, i-Iron↑, 1, Keap1↓, 22, Keap1↑, 2, Keap1↝, 2, ox-Keap1↑, 1, lipid-P?, 3, lipid-P↓, 247, lipid-P↑, 7, mt-lipid-P↓, 1, lipidDe↓, 1, MDA↓, 254, MDA↑, 12, MDA∅, 1, MPO↓, 29, MPO↑, 2, MPOD↑, 3, NADH↓, 1, NADPH/NADP+↑, 1, NFE2L2↓, 1, NOX↓, 6, NOX↑, 1, NOX1↓, 1, NOX2↓, 3, NOX4↓, 13, NQO1↑, 57, NQO1↝, 2, NQO1∅, 1, Nrf1?, 1, Nrf1↓, 1, Nrf1↑, 9, NRF2?, 1, NRF2↓, 18, NRF2↑, 407, NRF2⇅, 1, NRF2↝, 2, NRF2∅, 2, p‑NRF2↑, 2, ONOO↓, 1, PCO↓, 1, Prx↓, 1, Prx↑, 7, Prx4∅, 1, PrxII↑, 1, RNS↓, 11, ROMO1↑, 1, ROS?, 9, ROS↓, 1078, ROS↑, 58, ROS⇅, 13, ROS↝, 3, ROS∅, 26, i-ROS↑, 1, mt-ROS?, 1, mt-ROS↓, 10, mt-ROS↑, 4, RPM↑, 1, RPM↝, 1, SAM-e↓, 3, SAM-e↑, 1, selenoP↑, 20, SOD?, 2, SOD↓, 16, SOD↑, 368, SOD↝, 2, mt-SOD↑, 1, SOD1↓, 2, SOD1↑, 18, SOD2↓, 2, SOD2↑, 22, TAC↑, 51, TAC∅, 1, TBARS↓, 11, TBARS↑, 1, Thiols↓, 1, Thiols↑, 5, TOS↓, 3, TOS↑, 2, Trx↓, 2, Trx↑, 10, Trx1↑, 6, TrxR↓, 2, TrxR↑, 4, TrxR1↑, 4, UCPs↑, 2, UCPs↝, 1, uricA↓, 8, VitC↑, 16, VitE↓, 1, VitE↑, 8, xCT/SLC7A11↓, 2, xCT/SLC7A11↑, 5,

Metal & Cofactor Biology(tgid=2) ⓘ

Ferritin↓, 1, Ferritin↑, 2, FPN↑, 1, FTH1↓, 1, FTH1↑, 2, FTL↓, 1, IronCh↓, 1, IronCh↑, 55, IronCh↝, 1, Mets↝, 1, NCOA4↝, 1, TfR1/CD71↓, 5, TfR1/CD71↑, 1, Zn2+↓, 1,

Mitochondria & Bioenergetics(tgid=3) ⓘ

ADP:ATP↓, 1, compI↓, 2, compI↑, 2, compII↑, 1, compIII↓, 1, compIII↑, 2, compV↑, 1, DRP1/DNM1L↓, 11, DRP1/DNM1L↑, 3, p‑DRP1/DNM1L↝, 1, EGF↑, 1, ETC↓, 4, ETC↑, 3, ETC↝, 2, FIS1↓, 12, FIS1↑, 3, HSP60/HSPD1↓, 1, Insulin↓, 11, Insulin↑, 9, Insulin↝, 1, MCU↓, 1, MFN1↓, 1, MFN1↑, 3, MFN1↝, 1, MFN2↓, 2, MFN2↑, 8, MFN2↝, 1, mitResp↓, 3, mitResp↑, 10, mtDam↓, 35, mtDam↑, 1, NGB↑, 1, OCR↓, 4, OCR↑, 7, mt-OCR↑, 1, OPA1↓, 2, OPA1↑, 4, OXPHOS↓, 3, OXPHOS↑, 9, PDH↑, 1, PGC-1α↓, 3, PGC-1α↑, 33, PGC-1α↝, 2, PINK1↓, 1, PINK1↑, 4, SIRT3↑, 16, TFAM↑, 2, UCP1↓, 1, VDAC1↓, 1,

Core Metabolism/Glycolysis(tgid=4) ⓘ

12-HETE↓, 1, 12LOX↓, 10, 12LOX↑, 1, 15-LOX/ALOX15↓, 1, 3MST/MPST↑, 1, 5-HETE↓, 1, 5LO↓, 29, 5LO↝, 1, ACADS/SCAD↑, 1, ACC↓, 3, ACC↑, 3, p‑ACC↑, 1, mt-ACC⇅, 1, Acetyl-CoA↓, 2, Acetyl-CoA↑, 5, ACLY↓, 2, ACLY∅, 1, AcOH↑, 2, ACSL4↓, 4, ACSL4∅, 1, adiP↓, 2, adiP↑, 8, e-ADO↑, 1, ALAT?, 1, ALAT↓, 97, ALAT↑, 3, ALAT∅, 4, ALDOA↑, 1, ALDOC↑, 1, AMP↓, 1, AMPK↓, 4, AMPK↑, 75, AMPK⇅, 1, AMPK↝, 1, p‑AMPK↑, 8, ATP↓, 6, ATP↑, 56, ATP↝, 1, ATP∅, 1, mt-ATP↑, 1, BMAL1↑, 1, Buty↑, 4, cAMP↑, 9, CBS↑, 1, Cit/L-Cit↝, 1, cPLA2↓, 1, CPT1A↑, 1, CRM↓, 1, CRM↑, 11, CYP51/14LDM↑, 1, cytoP450↓, 2, DGAT1↓, 1, DHA↑, 3, DHODH↓, 1, ECAR↓, 5, ECAR↑, 2, ECAR∅, 1, Eic↓, 1, FABP4↓, 2, FAM↑, 1, FAO↓, 2, FAO↑, 7, mt-FAO↑, 1, FASN↓, 9, FFA/NEFA↓, 2, FFA/NEFA↝, 1, G6PD↑, 3, GAPDH↑, 1, GDH↓, 1, glucoNG↓, 3, glucose↓, 34, glucose↑, 3, glucose↝, 6, glucose∅, 1, GlucoseCon↓, 4, GlucoseCon↑, 22, GlutMet↑, 1, glyC↓, 1, Glycolysis↓, 9, Glycolysis↑, 10, Glycolysis↝, 4, GPI↑, 1, GSK‐3β↓, 48, GSK‐3β↑, 9, GSK‐3β↝, 1, p‑GSK‐3β↓, 2, p‑GSK‐3β↑, 8, H2S↑, 4, ac‑Histones↑, 1, HK1↑, 1, HK2↓, 8, HK2↑, 6, HMG-CoA↓, 3, KeyT↑, 5, KeyT↝, 2, lactateProd↓, 7, LDHA↓, 4, LDHA↑, 5, LDHB↑, 1, LDL↓, 73, lipidLev↓, 8, lipoGen↓, 2, LTB4↓, 1, LTC4↓, 2, MATs↓, 1, NAD↓, 1, NAD↑, 8, NAD↝, 1, NADH:NAD↑, 1, NADPH↓, 20, NADPH↑, 17, NADPH∅, 1, NH3↓, 3, NH3↑, 1, ODC1↝, 1, PA↑, 2, PDK1 / PDPK1↓, 2, p‑PDK1 / PDPK1↓, 1, PDKs↓, 2, PDKs↑, 1, PFK↓, 3, PFK↑, 1, PFK1↓, 1, PFK2↓, 1, PFKL↑, 3, PFKM↑, 2, PFKP↓, 1, PFKP↑, 1, PGC1A↑, 2, PGM1?, 1, PIP3↑, 1, PKM1↑, 2, PKM2↓, 18, PKM2↑, 8, PLA2↓, 2, polyA↝, 1, PONs↓, 1, PONs↑, 1, PPP↓, 2, SCD1↓, 1, SCFAs↑, 4, SCFAs∅, 1, SIRT1↓, 4, SIRT1↑, 80, SIRT1↝, 1, SIRT1∅, 1, SIRT2↑, 3, SREBF2↓, 1, SREBP1/SREBF1↓, 8, SREBP1/SREBF1↑, 1, SREBP2↓, 1, SREBP2↑, 1, TCA↑, 1, Warburg↓, 1,

Cell Death(tgid=5) ⓘ

AIF↓, 4, AIF↑, 1, APAF1↓, 2, Apoptosis↓, 154, Apoptosis↑, 5, Apoptosis∅, 2, mt-Apoptosis↓, 1, ASC?, 1, ASC↓, 5, ASK1↓, 2, BAD↓, 3, BAX↓, 60, BAX↑, 8, Bax:Bcl2↓, 13, Bax:Bcl2↑, 3, Bax:Bcl2↝, 1, Bcl-2↓, 10, Bcl-2↑, 51, Bcl-2↝, 1, Bcl-2∅, 1, Bcl-xL↓, 1, Bcl-xL↑, 2, BNIP3↓, 1, Casp↓, 4, Casp1?, 1, Casp1↓, 14, cl‑Casp1↓, 2, proCasp1↓, 2, Casp12↓, 7, Casp3?, 1, Casp3↓, 93, Casp3↑, 10, Casp3∅, 2, cl‑Casp3↓, 17, cl‑Casp3↑, 1, proCasp3↓, 2, Casp6↓, 1, Casp7↓, 1, Casp8↓, 3, Casp8↑, 1, cl‑Casp8↑, 3, Casp9↓, 28, Casp9↑, 4, Casp9∅, 1, cl‑Casp9↓, 4, cl‑Casp9↑, 1, cellD↓, 1, Cyt‑c↓, 23, Cyt‑c↑, 5, Cyt‑c∅, 4, Fas↓, 6, Fas↑, 2, FasL↓, 1, Ferroptosis↓, 29, Ferroptosis↑, 4, GranB/GZMB↓, 1, GRP58↓, 1, GSDMD?, 1, GSDMD↓, 3, HEY1↑, 1, IAP1↓, 1, iNOS↓, 130, iNOS↑, 6, MLKL↓, 1, necrosis↓, 4, p38↓, 21, p38↑, 6, p‑p38↓, 12, Pyro?, 1, Pyro↓, 5, RIP1↓, 1, survivin↓, 1, TUNEL↓, 1, YAP/TEAD↑, 2,

Kinase & Signal Transduction(tgid=6) ⓘ

Akt?, 1, Akt↓, 28, Akt↑, 68, Akt↝, 3, p‑Akt↓, 10, p‑Akt↑, 18, e-Akt↑, 1, AKT1↓, 2, AKT1↑, 1, p‑AKT1↑, 1, Akt2↓, 1, AMPKα↑, 2, CaMKII ↓, 2, CK2↓, 1, CK2↑, 1, CREB↓, 3, CREB↑, 30, CREB∅, 1, p‑CREB↑, 13, DYRK1A↓, 2, EGFR↓, 3, ERK↓, 27, ERK↑, 30, p‑ERK↓, 11, p‑ERK↑, 11, e-ERK↑, 1, HCAR2↑, 1, HER2/EBBR2↓, 1, HGF/c-Met↑, 2, Hippo↑, 1, IGF-1R↓, 1, IGFR↓, 1, IKKα↓, 5, IKKα↑, 1, p‑IKKα↓, 4, IκB?, 1, IκB↓, 2, IκB↑, 3, p‑IκB↓, 1, JAK↓, 4, p‑JAK1↓, 1, JAK2↓, 4, JAK2↑, 4, p‑JAK2↓, 2, JNK↓, 30, JNK↑, 4, p‑JNK↓, 13, p‑JNK↑, 4, p‑LIMK1↑, 1, LPAR1/EDG2↑, 1, MAPK?, 1, MAPK↓, 66, MAPK↑, 13, MAPK↝, 4, p‑MAPK?, 1, p‑MAPK↓, 3, MEK↓, 1, p‑MEK↓, 1, p‑MEK↑, 1, p‑MKK4↑, 1, Mst1↓, 2, mTOR↓, 25, mTOR↑, 17, mTOR↝, 2, p‑mTOR↓, 8, p‑mTOR↑, 3, p‑p70S6↓, 1, P70S6K↓, 3, p‑P70S6K↓, 1, p‑P70S6K↑, 1, PDGFR-BB↓, 2, PDGFR-BB↑, 1, PDGFRB↓, 1, PFKFB2↓, 1, PI3K↓, 25, PI3K↑, 53, PI3K↝, 2, p‑PI3K↓, 3, p‑PI3K↑, 1, PKA↑, 7, PKCδ?, 1, PKCδ↓, 4, PKCδ↑, 8, p‑PKCδ↑, 1, PP2A↑, 9, PROKR1↑, 1, PROKR2↑, 1, PTEN↓, 8, PTEN↑, 6, p‑PTEN↓, 1, p‑PTEN↑, 1, PTP1B↓, 2, Raf↓, 1, RAS↓, 2, RKIP↑, 1, Sp1/3/4↓, 6, Sp1/3/4↑, 1, Src↓, 1, STAT↓, 5, STAT3?, 1, STAT3↓, 18, STAT3↑, 6, STAT3↝, 1, p‑STAT3↓, 4, p‑STAT3↑, 1, STAT4↓, 1, STAT5↓, 1, STAT6↓, 1, STEP↓, 1, STK11/LKB1↑, 1,

Transcription & Epigenetics(tgid=7) ⓘ

Ac-histone H3↑, 1, AntiThr↑, 22, ATF2↑, 1, ATF4↓, 8, ATF4↑, 1, cJun↓, 5, p‑cJun↓, 5, cMyc↓, 2, cMyc↑, 1, p‑cMyc↑, 1, DNMT1↓, 6, DNMT3A↓, 3, DNMT3A↑, 1, DNMTs↓, 3, FOXO↑, 3, FOXO1↑, 2, FOXO1↝, 1, FOXO3?, 1, FOXO3↑, 7, H3↑, 1, ac‑H3↑, 1, H3K9↓, 1, H4↑, 1, ac‑H4↑, 1, HATs↓, 4, HDAC↓, 15, HDAC↑, 2, HDAC1↓, 2, HDAC2↓, 5, HDAC3↓, 4, HOTAIR↑, 1, KLF4↑, 1, MEF2D↑, 1, miR-107↑, 1, miR-155↓, 1, miR-22↑, 1, miR-23a-3p↓, 1, miR-29b↑, 1, miR-34a↓, 1, miR-34b-5p↓, 1, n-MYC↑, 1, OCT4↓, 1, other?, 24, other↓, 70, other↑, 131, other⇅, 2, other↝, 179, other∅, 6, PhotoS↑, 1, RUNX2↑, 2, RUNX2∅, 1, SOX18↑, 1, SOX2↑, 2, SOX9↑, 2, SUV39H↓, 1, TCF-4↓, 1, tumCV↓, 5, tumCV↑, 1, tumCV∅, 1,

Protein Folding & ER Stress(tgid=8) ⓘ

ATF6↓, 5, ChemChap↓, 1, ChemChap↑, 2, CHOP/DDIT3↓, 21, CHOP/DDIT3↑, 2, eIF2α↓, 3, p‑eIF2α↓, 3, cl‑eIF2α↑, 1, ER Stress↓, 53, ER Stress↑, 2, GRP78/BiP↓, 28, GRP78/BiP↑, 4, GRP94↑, 1, HSF1↑, 2, HSP27↓, 1, HSP27↑, 1, HSP70/HSPA5↓, 1, HSP70/HSPA5↑, 18, HSP70/HSPA5↝, 1, HSP90↓, 2, HSP90↑, 3, HSPs↓, 1, HSPs↑, 6, HSPs↝, 1, IRE1↓, 7, NQO2↑, 1, PDI↓, 1, PERK↓, 8, p‑PERK↓, 2, p‑PERK↑, 1, UPR↓, 5, UPR↑, 3, XBP-1↓, 4,

Autophagy & Lysosomes(tgid=9) ⓘ

ATG3↓, 1, ATG5↓, 1, ATG5↑, 2, ATG7↓, 1, autophagy↓, 2, autophagy↑, 1, autophagy↝, 1, Beclin-1/ATG6↓, 6, Beclin-1/ATG6↑, 11, CTSZ↓, 1, CTSZ↝, 1, LC3‑Ⅱ/LC3‑Ⅰ↓, 1, LC3‑Ⅱ/LC3‑Ⅰ↑, 3, LC3A↑, 1, LC3B↓, 1, LC3B↑, 3, LC3II↓, 2, LC3II↑, 5, LC3s↓, 1, lysosome↑, 1, MitoP↓, 1, MitoP↑, 7, p62↓, 9, p62↑, 7, PARK2↑, 7, TFEB↑, 1, ULK1/ATG1↑, 1,

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 1, ATR↑, 1, DNAdam↓, 61, DNAdam↑, 3, DNAdam∅, 1, DNArepair↑, 6, importin α/β↓, 1, p16↓, 2, P53↓, 12, P53↑, 7, P53↝, 1, PARP↓, 3, PARP↑, 1, PARP∅, 1, p‑PARP↓, 1, cl‑PARP↓, 2, cl‑PARP↑, 2, PARP1↓, 1, cl‑PARP1↓, 1, PCNA↓, 4, PCNA↑, 1, RAD51↓, 1, SIRT6↑, 3, Telomerase↓, 1, TOP2↑, 1, TP53↑, 1, γH2AX↓, 1, p‑γH2AX↓, 1,

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1, CDK2↓, 2, CDK4↓, 1, CDK5↓, 9, cellSen↓, 1, cellSen↑, 1, cycA1/CCNA1↓, 1, CycB/CCNB1↓, 1, cycD1/CCND1↓, 4, cycE/CCNE↓, 1, cycE/CCNE↑, 1, E2Fs↑, 2, GADD34↓, 1, GADD45A↑, 1, Ki-67↓, 4, Ki-67↑, 2, P21↓, 6, P21↑, 6, RB1↓, 1, TumCCA↑, 8,

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↑, 1, BMP2↑, 3, BMPs↓, 1, BMPs↑, 2, CD133↑, 1, CD34↑, 1, CEBPA↓, 2, cFos↓, 1, cFos↑, 1, CHIP↑, 1, Choline↑, 3, CLOCK↝, 2, Diff↓, 2, Diff↑, 14, Diff↝, 2, EP2↓, 1, EP2↑, 1, EP300↓, 2, FGF↑, 7, GH↑, 3, Gli1↑, 1, HH↓, 2, HMGCR↓, 2, IGF-1↓, 9, IGF-1↑, 16, IGFBP1↑, 1, IGFBP3↓, 1, IGFBP3↑, 1, Jun↓, 1, Jun↑, 1, Ki-67↓, 4, Ki-67↑, 2, MSCs↑, 1, mTORC1↓, 3, Nestin↑, 1, neuroG↑, 17, NOTCH↓, 1, NOTCH↑, 1, NOTCH1↑, 2, p300↓, 1, Shh↓, 1, Shh↑, 1, STAT1↓, 1, p‑STAT1↓, 1, TumCG↓, 4, TumCG↑, 1, TumCG∅, 1, TumCP↓, 9, TumCP↑, 1, tyrosinase↓, 2, Wnt↓, 3, Wnt↑, 4, Wnt/(β-catenin)↓, 1, Zn2+↓, 1,

Migration(tgid=13) ⓘ

ACTA2↓, 1, AntiAg↓, 3, AntiAg↑, 98, AntiAg∅, 3, AP-1↓, 18, AP-1↑, 1, ARG1/2↑, 2, mt-ATPase↑, 1, BACH1↓, 1, Ca+2?, 3, Ca+2↓, 47, Ca+2↑, 20, Ca+2↝, 14, Ca+2∅, 1, p‑Ca+2↓, 1, i-Ca+2↓, 2, mt-Ca+2↓, 1, cal2↓, 5, Cartilage↑, 11, p‑Cofilin↓, 1, p‑Cofilin↑, 1, COL1↓, 6, COL1↑, 2, COL1∅, 1, COL1A1↓, 1, COL2A1↑, 2, COL3A1↓, 3, E-cadherin↓, 1, E-cadherin↑, 7, EMT↓, 7, EMT↑, 2, F-actin↓, 1, F-actin↑, 1, FAK↑, 2, Fibronectin↓, 2, Fibrosis↓, 1, FLRT2↑, 1, FNDC5↑, 1, GIT1↑, 1, heparanase↑, 1, ITGA5↓, 1, ITGB1↓, 1, ITGB1↑, 1, LAMs↑, 1, LRP1↑, 3, MLC2/MYL9↝, 1, p‑MLC2/MYL9↑, 1, MMP-10↓, 1, MMP-10↝, 1, MMP1↓, 5, MMP11↑, 1, MMP13↓, 8, MMP2↓, 14, MMP2↑, 6, MMP3↓, 5, MMP3↑, 2, MMP7↓, 1, MMP9↓, 32, MMP9↑, 6, MMPs↓, 9, MMPs↑, 3, MUC1↑, 3, MYPT1 / PPP1R12A↑, 1, p‑MYPT1 / PPP1R12A↑, 1, N-cadherin↓, 1, N-cadherin↑, 2, Na+↑, 2, Na+↝, 1, Netrins↑, 1, NFAM1↑, 1, NFAT↓, 1, NFAT↑, 2, OPN↑, 1, PAI-1/SERPINE1↓, 1, PDGF↓, 1, PDGF↑, 1, PROK2↑, 1, proline↝, 1, Rac1↑, 1, p‑Rac1↓, 1, Rho↓, 7, ROCK1↓, 7, ROCK1↑, 1, Sema3A/PlexinA1↑, 1, serineP↓, 1, SLIT2↑, 1, Smad1↑, 1, p‑Smad1↑, 1, SMAD2↓, 1, p‑SMAD2↓, 3, SMAD3↓, 3, p‑SMAD3↓, 1, p‑SMAD3↑, 1, SMAD4↑, 1, SMAD5↑, 1, p‑SMAD5↑, 1, Smad7↑, 2, Snail↓, 1, Snail↑, 1, SPARC↓, 1, STAC2↑, 1, p‑T-cadherin↓, 2, TG2/TGase↓, 4, TGF-β↓, 21, TGF-β↑, 12, TGF-β1↓, 6, TGF-β1↑, 4, TIMP1↓, 5, TIMP1↑, 3, TIMP2↑, 3, TregCell↑, 1, TumCI↓, 2, TumCI∅, 1, TumCMig↓, 3, TumCMig↑, 1, TumCMig∅, 1, TumMeta↓, 2, Twist↑, 1, TXNIP↓, 8, TXNIP↑, 2, Tyro3↓, 1, uPA↓, 1, Vim↓, 9, Vim↑, 1, Zeb1↓, 1, α-SMA↓, 19, α-SMA↑, 1, α-SMA↝, 1, α-tubulin↓, 2, β-catenin/ZEB1↓, 4, β-catenin/ZEB1↑, 8, β-catenin/ZEB1↝, 1,

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG?, 1, angioG↓, 14, angioG↑, 26, angioG↝, 1, CD31/PECAM-1↓, 2, CD31/PECAM-1↑, 3, E-sel↓, 6, ECM/TCF↑, 1, EGR4↑, 1, Endoglin↑, 1, eNOS↓, 2, eNOS↑, 7, p‑eNOS↑, 2, HIF-1↓, 1, Hif1a↓, 19, Hif1a↑, 14, Hif1a↝, 1, Hif1a∅, 2, HIF2a↑, 1, Hypoxia↓, 1, LOX1↓, 2, NO?, 1, NO↓, 110, NO↑, 17, NPY↑, 1, P-sel↓, 1, REL↑, 1, TXA2↓, 8, VCAM-1↓, 21, VEGF↓, 22, VEGF↑, 31, VEGFR2/KDR/Flk1↓, 1, VEGFR2/KDR/Flk1↑, 1, p‑VEGFR2/KDR/Flk1↓, 1,

Barriers & Transport(tgid=15) ⓘ

AQPs↓, 3, AQPs↑, 3, pol-AQPs↑, 1, BBB?, 3, BBB↓, 9, BBB↑, 161, BBB↝, 14, BBB∅, 4, CellMemb↑, 6, CLDN1↓, 2, CLDN1↑, 2, CLDN1↝, 1, CLDN3↑, 1, CLDN4↑, 1, CLDN5↓, 1, CLDN5↑, 1, EPR↑, 3, GastroP↑, 15, GLUT1↓, 2, GLUT1↑, 5, GLUT2↑, 2, GLUT3↑, 5, GLUT4↓, 1, GLUT4↑, 10, GlyFlow↑, 3, H+/K+-ATPase↓, 1, IBI↑, 12, LAT↑, 1, MMP↓, 16, MMP↑, 77, MMP⇅, 1, MMP↝, 2, MMP∅, 4, MPT↑, 1, MUC19↓, 1, MUC2↓, 1, MUC5AC↓, 2, Na+↑, 2, Na+↝, 1, NHE3↑, 1, OATPs↓, 3, OCLN↓, 3, OCLN↑, 6, OCLN↝, 1, SVCT-2↑, 1, TJ↓, 1, TJ↑, 6, TJ↝, 1, TRPA1↑, 2, TRPC1↓, 1, TRPC1↑, 1, TRPM7↓, 4, TRPM7⇅, 1, TRPM7↝, 1, TRPV1↑, 8, TRPV3↑, 2, VGCC↓, 1, VGCC↑, 2, VGCC⇅, 1, VGCC↝, 1, VGSC↓, 1, VGSC↑, 1, Vm/CMP↑, 2, ZO-1↓, 5, ZO-1↑, 12, ZO-1↝, 1,

Immune & Inflammatory Signaling(tgid=16) ⓘ

AIF1/Iba-1↓, 3, AIM2↓, 2, BALF-Infl↓, 3, BALF-Lym↓, 1, CB2 / CNR2↑, 5, CCL11↓, 2, CD14↑, 1, CD19↑, 1, CD25+↓, 1, CD25+↑, 1, CD4+↑, 8, CD69↓, 1, CD8+↑, 4, cGAS–STING↓, 2, COX1↓, 24, COX1↑, 1, COX2/PTGS2?, 1, COX2/PTGS2↓, 206, COX2/PTGS2↑, 2, COX2/PTGS2∅, 1, CTLA-4↓, 1, CXCc↓, 2, CXCc↑, 1, CXCL1↓, 1, CXCL12↑, 1, CXCL15↓, 1, CXCR2↑, 1, CXCR4↓, 2, DCells↑, 1, Dectin1↑, 1, DR4↓, 1, Eos↓, 8, p‑FcεRI↓, 1, FOXP3↑, 2, GM-CSF↓, 1, GM-CSF↑, 1, HCAR2↑, 1, HMGB1↓, 11, ICAM-1↓, 23, IFN-γ↓, 26, IFN-γ↑, 10, IFN-γ∅, 1, IgE↓, 7, IgG1↓, 1, IL1?, 1, IL1↓, 18, IL1↑, 1, IL10?, 1, IL10↓, 21, IL10↑, 44, IL10∅, 1, IL12↓, 10, IL12↑, 1, IL13↓, 7, IL17↓, 20, IL17↑, 2, IL17∅, 1, IL18↓, 11, IL18↑, 1, IL1RL1/ST2↓, 1, IL1α↓, 2, IL1α∅, 1, IL1β↓, 234, IL1β↑, 2, IL1β∅, 1, IL2↓, 17, IL2↑, 6, IL22↓, 3, IL23↓, 4, IL33↓, 3, IL4↓, 23, IL4↑, 10, IL4∅, 1, IL5↓, 11, IL5↑, 1, IL6?, 3, IL6↓, 260, IL6↑, 11, IL8↓, 45, IL8↑, 1, IL8∅, 1, ILC2↓, 1, Imm↓, 2, Imm↑, 73, Imm⇅, 2, Imm↝, 2, INF-γ↓, 3, Inflam?, 7, Inflam↓, 1005, Inflam↑, 15, Inflam∅, 2, IP-10/CXCL-10↓, 1, IP-10/CXCL-10↑, 1, IRF3↓, 4, LIF↑, 1, LPS↓, 3, LTA/TNF-β↓, 1, LTA/TNF-β↑, 1, M1↓, 1, M2 MC↑, 2, pol-M2 MC↑, 2, Macrophages↓, 1, MCP1/CCL2↓, 26, MCP1/CCL2↑, 2, MCP1/CCL2↝, 1, MCP1/CCL2∅, 1, MCT1↓, 1, MIP‑1α/CCL3↓, 5, MIP2↓, 3, mPGES-1↓, 1, MyD88↓, 10, NeuroI↓, 15, Neut↓, 3, Neut↑, 2, NF-kB?, 1, NF-kB↓, 357, NF-kB↑, 9, p‑NF-kB↓, 9, NK cell↑, 10, NLRP3↓, 91, NLRP3↑, 3, NOD1↓, 1, OSM↑, 1, p‑p50↓, 1, p65↓, 9, p‑p65↓, 3, PAF↓, 2, PAF↑, 2, PAR-2↓, 1, PGD2↓, 1, PGE1↓, 1, PGE2↓, 76, PGE2↑, 3, PSA↓, 2, PSA∅, 1, RAGE↓, 8, RANTES↓, 5, SOCS-3↓, 1, T-Cell↑, 1, Th1 response↓, 2, Th1 response↑, 1, Th17↓, 1, Th2↓, 3, Th2↑, 2, TLR1↓, 3, TLR2↓, 10, TLR3↓, 1, TLR4↓, 43, TLR4↑, 1, TLR4∅, 1, TNF-α?, 1, TNF-α↓, 372, TNF-α↑, 12, TRAF1↓, 1, TRAF6↓, 1, Treg lymp↓, 1, Treg lymp↑, 1, Treg lymp↝, 1, TREM-1↓, 1, TRIF↓, 3, VitD↑, 6, β-HEX↓, 2,

Cellular Microenvironment(tgid=17) ⓘ

ADAM17↑, 2, Astr↓, 2, GFAP↓, 6, GGT/CD224↓, 1, MGlio↓, 1, pH↓, 1, pH↑, 1, pH↝, 2, Temp↝, 1, TREM2↓, 1,

Synaptic & Neurotransmission(tgid=18) ⓘ

5-AR↓, 1, 5HT↓, 4, 5HT↑, 34, Ach?, 1, Ach↑, 48, AChE↓, 201, AChE↑, 3, AChE↝, 2, AChE∅, 5, ADAM10↑, 16, ADAM10↝, 2, BChE?, 1, BChE↓, 36, BChE∅, 1, BDNF↓, 4, BDNF↑, 217, BDNF⇅, 1, BDNF↝, 1, BDNF∅, 8, BrainVol↑, 3, BrainVol↝, 1, BrainVol∅, 3, ChAT↑, 22, ChE↓, 1, CHRM1↑, 1, DA↑, 1, DHCR7↑, 1, EndoR↑, 1, GABA↓, 4, GABA↑, 15, GABA↝, 1, GAD1/GAD67↑, 1, GDNF↑, 1, MAOA↓, 17, MAOA↑, 1, MAOA↝, 1, MAOB↓, 8, monoA↓, 1, monoA↑, 3, NGF↑, 15, NMDAR↑, 1, p‑NMDAR↑, 1, NTF3/NT-3↑, 1, PSD95?, 1, PSD95↑, 16, RELN↑, 1, SNAP25↑, 2, SYN1↑, 1, SYN3↓, 1, SYP↑, 2, SYT1↑, 1, TPH1↓, 1, TrkB↓, 2, TrkB↑, 25, TrkB↝, 1, β-Endo↑, 2,

Protein Aggregation(tgid=19) ⓘ

AEP↓, 1, AGEs↓, 16, APOE4↓, 1, APP↓, 27, APP∅, 2, cl‑APP↓, 1, cl‑APP↑, 1, Aβ?, 1, Aβ↓, 334, Aβ↑, 3, Aβ∅, 6, Aβ42↓, 11, BACE/β-secretase↓, 78, BACE/β-secretase↑, 3, BACE/β-secretase↝, 1, IDE↑, 3, NEP↑, 1, PSEN1/PS1↓, 2, PSEN1/PS1↑, 1, PSEN2/PS-2↓, 1, QPCT/QC↓, 1, tau?, 1, tau↓, 63, p‑tau↓, 94, XO↓, 6, XO↝, 1, β-Amyloid↓, 5,

Hormonal & Nuclear Receptors(tgid=20) ⓘ

2/16-OHE1↑, 1, ACE/ACE1↓, 6, ACE2↓, 1, AHR↓, 1, AhR↑, 4, AKR1C3/17β-HSD5/PGF Synthase↑, 1, ARNT↑, 1, BNP↓, 1, cortisol↓, 2, cortisol↑, 1, CYP19↓, 2, DHT↓, 1, DHT↑, 1, END↑, 2, ENL↑, 1, ER(estro)↓, 1, ER(estro)↑, 2, ERβ/ESR2↑, 1, Estro↓, 1, FGF21↑, 4, GLP-1R↑, 1, GPER↑, 1, GR↓, 1, GR↑, 5, GR↝, 1, Leptin↓, 1, PPARα↑, 14, PPARα↝, 1, PPARγ↓, 8, PPARγ↑, 30, p‑PPARγ↓, 1, PR↝, 1, RAAS↓, 1, SHBG↓, 1, testos↓, 1, testos↑, 5, testos?, 1, TSHR↓, 1, VDR↑, 1,

Drug Metabolism & Resistance(tgid=21) ⓘ

ABC↓, 1, AKR1B1/ALR2↑, 1, AKR1B10↝, 1, BioAv?, 4, BioAv↓, 206, BioAv↑, 340, BioAv⇅, 4, BioAv↝, 152, BioAv∅, 2, BioEnh↑, 35, BioEnh↝, 1, CES2↓, 1, ChemoSen↑, 4, CompStab↓, 3, CompStab↑, 14, CompStab↝, 5, CYP1A1↓, 3, CYP1A1↑, 1, CYP1A2↑, 1, CYP1B1↓, 1, CYP2A3/CYP2A6↝, 1, CYP2C19↓, 1, CYP2C6↓, 2, CYP2C6↑, 1, CYP2C8↓, 1, CYP2C9↓, 1, CYP2D1↑, 1, CYP2D6↓, 2, CYP2E1↓, 8, CYP3A2↓, 2, CYP3A2↑, 1, CYP3A4↓, 6, CYP3A4↑, 1, DDS↑, 5, Dose?, 22, Dose↓, 15, Dose↑, 39, Dose⇅, 4, Dose↝, 466, Dose∅, 10, eff?, 2, eff↓, 37, eff↑, 260, eff↝, 35, eff∅, 2, GSTA1↓, 2, GSTA1↑, 13, GSTP1/GSTπ↓, 1, Half-Life?, 2, Half-Life↓, 37, Half-Life↑, 27, Half-Life⇅, 1, Half-Life↝, 83, Half-Life∅, 6, MRP↓, 1, MRP1/ABCC1↓, 1, P-gp/ABCB1↓, 12, P-gp/ABCB1↑, 2, P450↓, 7, P450↑, 2, P450↝, 1, RadioS↑, 1, selectivity↑, 11, selectivity⇅, 1, Synergy↑, 73, TET2↑, 1, UGT1A↓, 1,

Clinical Biomarkers(tgid=22) ⓘ

ALAT?, 1, ALAT↓, 97, ALAT↑, 3, ALAT∅, 4, ALB↑, 4, ALB↝, 1, ALP↓, 22, ALP↑, 2, ALP∅, 1, anemia↓, 1, ascitic↓, 1, AST↓, 96, AST↑, 3, AST∅, 4, BG↓, 9, Bil↓, 5, Bil↑, 2, BloodF↓, 1, BloodF↑, 22, BMD↑, 31, BP?, 2, BP↓, 73, BP↝, 1, BP∅, 3, BUN?, 1, BUN↓, 13, BUN↑, 1, Calcium↑, 2, Calcium↝, 2, CCr / CrCl↓, 1, CCr / CrCl∅, 1, CEA↓, 2, colonLen↑, 1, creat↓, 27, creat↑, 2, CRP↓, 32, EGFR↓, 3, Ferritin↓, 1, Ferritin↑, 2, FEV1↑, 2, HbA1c↓, 1, Hcy/homoC↓, 24, Hcy/homoC↝, 2, HemoG↑, 2, HER2/EBBR2↓, 1, HOMA↓, 1, HRV↑, 1, hs-CRP↓, 6, IL6?, 3, IL6↓, 260, IL6↑, 11, IRes↓, 3, IRes↑, 2, IRes↝, 1, LDH↓, 42, LDH↑, 3, LDH∅, 1, Mag↑, 2, NLR↓, 2, NOS2↓, 8, NSE↑, 1, OCN↑, 1, OCN∅, 1, PEF↑, 1, PSA↓, 2, PSA∅, 1, PV↓, 4, RAGE↓, 8, RBC↑, 2, rHR↓, 1, SpO2↑, 1, TC↓, 4, TG/TAG↓, 9, TMAO↓, 4, TMAO↑, 7, TMAO⇅, 1, TMAO∅, 2, TP53↑, 1, UFR?, 1, UFR↑, 3, UR↓, 2, Urea↓, 5, VitD↑, 6,

Functional Outcomes(tgid=23) ⓘ

Airway↓, 3, AirwayM↓, 4, Analgesic↑, 5, Anger↓, 1, AntiAge↑, 50, AntiAge⇅, 1, antiAll?, 1, antiAll↑, 77, antiAll∅, 1, AntiArt↑, 24, AntiCan?, 1, AntiCan↓, 4, AntiCan↑, 94, antiCG↑, 1, antiCG↝, 1, antiD↓, 1, AntiDiabetic↓, 4, AntiDiabetic↑, 117, antiM↑, 1, AntiMyl↑, 1, antiNeop↑, 1, antiPs↑, 5, antiPy↑, 1, AntiTum↓, 2, AntiTum↑, 31, ANXi↓, 4, Appetite↓, 1, BDI↓, 1, BOLD↑, 2, Bone Healing↑, 1, BowelM↑, 1, cachexia↓, 1, cachexia↑, 1, cardioP?, 2, cardioP↓, 4, cardioP↑, 263, cardioP⇅, 1, cardioP∅, 1, CardioT↓, 4, chemoP↑, 41, chemoPv↑, 32, ChemoSideEff↓, 1, cognitive?, 3, cognitive↓, 16, cognitive↑, 593, cognitive↝, 9, cognitive?, 1, cognitive∅, 27, cough?, 1, CryoP↑, 2, cytoP↑, 2, DCR∅, 1, diuretic↑, 10, fatigue↓, 6, GFR↓, 1, GFR↑, 1, GFR∅, 1, Hear↑, 1, hepatoP↓, 10, hepatoP↑, 247, IPSS↓, 1, IPSS↝, 1, Learn?, 2, Learn↑, 27, memory?, 4, memory↓, 4, memory↑, 411, memory∅, 6, Mood?, 1, Mood↑, 49, Mood⇅, 1, Mood↝, 1, motorD↓, 3, motorD↑, 67, Mucositis↓, 3, MusCon↓, 2, Nausea↓, 1, neuroP?, 4, neuroP↓, 5, neuroP↑, 711, neuroP↝, 1, NMSS↓, 1, NP/CIPN↓, 4, Obesity↓, 54, ORR∅, 1, OS↓, 1, OS↑, 44, Pain↓, 43, PDE4↓, 2, PFS∅, 1, QoL?, 1, QoL↑, 25, QoL∅, 1, radioP↑, 48, RenoP↓, 2, RenoP↑, 92, RenoP↝, 2, Risk↓, 75, Risk↑, 14, Risk↝, 2, Risk∅, 3, RT↓, 2, Sleep↑, 25, Sleep∅, 1, SoreThr?, 1, Strength↓, 1, Strength↑, 15, Stress↓, 10, Stroke↓, 47, Stroke↑, 1, Stroke↝, 1, Tinn↓, 4, toxicity?, 6, toxicity↓, 323, toxicity↑, 37, toxicity⇅, 2, toxicity↝, 76, toxicity∅, 70, UPDRS↓, 1, UPDRSIII∅, 1, Vomit↓, 1, Weight↓, 18, Weight↑, 4, Weight↝, 3, Weight∅, 4, Wound Healing↓, 2, Wound Healing↑, 40,

Infection & Microbiome(tgid=24) ⓘ

AntiBio↓, 1, AntiBio↑, 61, AntiFungal↓, 2, AntiFungal↑, 32, AntiP↓, 1, AntiP↑, 15, AntiViral↑, 45, Bacteria?, 1, Bacteria↓, 137, Bacteria↑, 1, Dectin1↑, 1, Diar↓, 9, Dysb↓, 2, GutMicro↓, 1, GutMicro↑, 128, GutMicro↝, 9, GutMicro∅, 2, Inf↓, 4, insect↑, 1, Sepsis↓, 28,

Ingredients & Constituents(tgid=25) ⓘ

Api↑, 1, CA↑, 1, Catechins↑, 1, FA↑, 1, Fibre↑, 1, Flav↑, 1, GA↑, 1, Ingr?, 3, Ingr↑, 7, Ingr↝, 25, LT↑, 1, Myr↑, 1, Phen↑, 2, Poly↑, 1, QC↑, 2,
Total Targets: 1620

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

Cancer Database Query Results

Pathway results for Effect on Cancer / Diseased Cells:

NA, unassigned(tgid=0) ⓘ

Redox & Oxidative Stress(tgid=1) ⓘ

Metal & Cofactor Biology(tgid=2) ⓘ

Mitochondria & Bioenergetics(tgid=3) ⓘ

Core Metabolism/Glycolysis(tgid=4) ⓘ

Cell Death(tgid=5) ⓘ

Kinase & Signal Transduction(tgid=6) ⓘ

Transcription & Epigenetics(tgid=7) ⓘ

Protein Folding & ER Stress(tgid=8) ⓘ

Autophagy & Lysosomes(tgid=9) ⓘ

DNA Damage & Repair(tgid=10) ⓘ

Cell Cycle & Senescence(tgid=11) ⓘ

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Migration(tgid=13) ⓘ

Angiogenesis & Vasculature(tgid=14) ⓘ

Barriers & Transport(tgid=15) ⓘ

Immune & Inflammatory Signaling(tgid=16) ⓘ

Cellular Microenvironment(tgid=17) ⓘ

Synaptic & Neurotransmission(tgid=18) ⓘ

Protein Aggregation(tgid=19) ⓘ

Hormonal & Nuclear Receptors(tgid=20) ⓘ

Drug Metabolism & Resistance(tgid=21) ⓘ

Clinical Biomarkers(tgid=22) ⓘ

Functional Outcomes(tgid=23) ⓘ

Infection & Microbiome(tgid=24) ⓘ

Ingredients & Constituents(tgid=25) ⓘ

Pathway results for Effect on Normal Cells:

NA, unassigned(tgid=0) ⓘ

Redox & Oxidative Stress(tgid=1) ⓘ

Metal & Cofactor Biology(tgid=2) ⓘ

Mitochondria & Bioenergetics(tgid=3) ⓘ

Core Metabolism/Glycolysis(tgid=4) ⓘ

Cell Death(tgid=5) ⓘ

Kinase & Signal Transduction(tgid=6) ⓘ

Transcription & Epigenetics(tgid=7) ⓘ

Protein Folding & ER Stress(tgid=8) ⓘ

Autophagy & Lysosomes(tgid=9) ⓘ

DNA Damage & Repair(tgid=10) ⓘ

Cell Cycle & Senescence(tgid=11) ⓘ

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Migration(tgid=13) ⓘ

Angiogenesis & Vasculature(tgid=14) ⓘ

Barriers & Transport(tgid=15) ⓘ

Immune & Inflammatory Signaling(tgid=16) ⓘ

Cellular Microenvironment(tgid=17) ⓘ

Synaptic & Neurotransmission(tgid=18) ⓘ

Protein Aggregation(tgid=19) ⓘ

Hormonal & Nuclear Receptors(tgid=20) ⓘ

Drug Metabolism & Resistance(tgid=21) ⓘ

Clinical Biomarkers(tgid=22) ⓘ

Functional Outcomes(tgid=23) ⓘ

Infection & Microbiome(tgid=24) ⓘ

Ingredients & Constituents(tgid=25) ⓘ

Home Page